Hims & Hers price target raised to $27 from $25 at Citi

Citi raised the firm’s price target on Hims & Hers to $27 from $25 and keeps a Sell rating on the shares post the Q4 report. The focus on the earnings call was on the durability of Hims & Hers’ weight loss offerings given the removal of semaglutide from the FDA’s shortage list, the analyst tells investors in a research note. The firm believes the company has “multiple avenues for growth,” and expects category expansion into hormonal therapies this year. However, it awaits a better entry point for the shares and more details on Hims & Hers’ growth outside of GLP-1s.